Clinical application and research progress of statins in the treatment of acute myocardial infarction
TAN Zhihui1 GUO Ruiwei2 TAN Zhisheng2 LIU Dan3 GUO Shuo4
1.Department of Geriatrics, Kunming General Hospital of Chengdu Military Command, Yunnan Province, Kunming 650032, China;
2.Department of Cardiology, Kunming General Hospital of Chengdu Military Command, Yunnan Province, Kunming 650032, China;
3.Department of General Medicine, Kunming Tongren Hospital, Yunnan Province, Kunming 650032, China;
4.Department of Internal Medicine, Kunming Guangfu Hospital, Yunnan Province, Kunming 650032, China
Abstract：Statins, the 3- hydroxyl -3 methyl amyl two acyl coenzyme A (HMG-CoA) reductase inhibitor, are the most effective lipid lowering drugs at present. It can not only reduce the total cholesterol (TC) and the low density lipoprotein (LDL), but also reduce the TG and increase the density lipoprotein (HDL) to a certain extent, it is called a comprehensive lipid-lowering drug. The mechanism of statins is to synthesize the enzyme HMG-CoA reductase by competitive inhibition of endogenous cholesterol, blocking the intracellular pathway of hydroxymethylene valerate metabolism, reducing the cholesterol synthesis in cells, and increasing the number and activity of LDL receptor on the surface of the membrane on the membrane, so that serum cholesterol is increased, which is mainly used to reduce cholesterol, especially low density lipoprotein cholesterol in clinic, and to treat atherosclerosis, is the most effective drug for the prevention and treatment of coronary heart disease. In recent years, it has been found that statins have many non lipid-lowering effects, including inhibition of atherosclerosis and thrombosis, remission of rejection after organ transplantation, treatment of osteoporosis, antitumor, and anti Alzheimer′s disease. But, combined with the pathogenesis of acute myocardial infarction, this article expounded the mechanism of statins on acute myocardial infarction, and summarized its serial role in acute myocardial infarction, so as to provide theoretical basis and guidance for clinical medication.
谭志晖1 郭瑞威2 谭志胜2 刘丹3 郭硕4. 他汀类药物在治疗急性心肌梗死的临床应用和研究进展[J]. 中国医药导报, 2018, 15(20): 21-24.
TAN Zhihui1 GUO Ruiwei2 TAN Zhisheng2 LIU Dan3 GUO Shuo4. Clinical application and research progress of statins in the treatment of acute myocardial infarction. 中国医药导报, 2018, 15(20): 21-24.
[1] 雷锐.不同剂量他汀类药物对早期急性心肌梗死的临床效果和安全性分析[J].中西医结合心脑血管病杂志，2017， 15（9）：1078-1080.
[2] 葛广豪，龚勇，马江伟，等.不同负荷剂量他汀类药物对老年急性心肌梗死直接介入治疗术后心肌细胞的影响[J].中华老年心脑血管病杂志，2016，18（9）：899-904.
[3] 龚勇，葛广豪，马江伟，等.不同负荷量他汀类药物对急性心肌梗死直接PCI术后心肌细胞的影响[J].中国心血管病研究，2016，14（11）：1038-1043.
[4] 金晓萍，张俊杰.他汀类药物对早发冠心病 急性心肌梗死患者心脏及血管内皮功能改善研究[J].北华大学学报：自然科学版，2017，18（5）：630-632.
[5] 赵春勇，高筱红，金洪珍，等.不同他汀类药物联合比伐卢定对急性心梗患者PCI术后心肌功能、血凝状态及炎症因子水平的影响[J].海南医学，2016，27（23）：3838-3840.
[6] 陈洪云，刘玲，吴猛，等.参附注射液联合阿司匹林与氯吡格雷和低分子肝素治疗急性心肌梗死的急救体会[J].中国中西医结合急救杂志，2016，23（4）：431-432.
[7] 朱乔燕，王光宇，张庆勇.他汀类药物非调脂作用在改善心肌梗死后心脏结构与功能方面的研究进展[J].医学综述，2016，22（17）：3424-3427.
[8] 裴源源，马云晖，马晓路，等.急性心肌梗死病例致急性肾损伤危险因素分析[J].中华急诊医学杂志，2016，25（9）：1166-1170.
[9] 肖立运，李秀丽.瑞舒伐他汀联合非诺贝特治疗急性心肌梗死合并糖尿病的疗效及炎性因子的影响[J].中国老年保健医学，2017，15（2）：55-57.
[10] Zullo AR，Sharmin S，Lee Y，et al. Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents [J]. J Am Geriatr Soc，2017，65（11）：2397-2404.
[11] Mosholder AD，Lee JY，Zhou EH，et al. Long-Term Risk of Acute Myocardial Infarction，Stroke，and Death With Outpatient Use of Clarithromycin：A Retrospective Cohort Study [J]. Am J Epidemiol，2018，187（4）：786-792.
[12] Sim DS，Jeong MH. Differences in the Korea Acute Myocardial Infarction Registry Compared with Western Registries [J]. Korean Circ J，2017，47（6）：811-822.
[13] Wei CC，Lee SH. Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome - Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry [J]. Acta Cardiol Sin，2017，33（4）：377-383.
[14] Korhonen MJ，Robinson JG，Annis IE，et al. Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction [J]. J Am Coll Cardiol，2017，70（13）：1543-1554.
[15] Schwartz GG，Ballantyne CM，Barter PJ，et al. Association of Lipoprotein（a） With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome：Analysis of the dal-Outcomes Randomized Clinical Trial [J]. JAMA Cardiol，2018，3（2）：164-168.
[16] 鞠昌瑛.美托洛尔与他汀类药联合治疗心肌梗死的疗效观察[J].中国医院用药评价与分析，2014，14（2）：148-150.
[17] 崔芳.血脂康在他汀类药物致肝酶升高的不稳定型心绞痛老年患者中的疗效[J].中国老年学杂志，2015，35（1）：221-222.
[18] 戴敬，孟康，吕树铮.他汀类药物对急性心肌梗死患者应激性高血糖的影响[J].中国循证心血管医学杂志，2014， 6（2）：160-161.
[19] 刘文民，陈国藩，菅颖，等.长期应用他汀类药物对急性心肌梗死PCI术中慢血流或无复流现象的影响[J].医学研究杂志，2014，43（6）：104-107.
[20] Xie S，Zhou J. Effect of statins and the clinical nursing characteristics in patients with acute myocardial infarction [J]. Pak J Pharm Sci，2017，30（5）：1843-1849.
[21] Eindhoven DC，van Staveren LN，van Erkelens JA，et al. Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands [J]. Neth Heart J，2018，26（1）：13-20.
[22] Cho J，Park IB，Lee K，et al. Statin has more protective effects in AMI patients with higher plasma BNP or NT-proBNP level，but not with lower left ventricular ejection fraction [J]. J Cardiol，2018，71（4）：375-381.
[23] Gurgel MHC，Montenegro Junior RM，Melo Ponte CM，et al. Metabolic syndrome，diabetes and inadequate lifestyle in first-degree relatives of acute myocardial infarction survivors younger than 45 years old [J]. Lipids Health Dis，2017，16（1）：224.
[24] Ren Y，Zhu H，Fan Z，et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction [J]. Exp Ther Med，2017，14（5）：4942-4950.
[25] Gong IY，Yan AT，Ko DT，et al. Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer，1995 to 2013 [J]. Cancer，2018，124（6）：1269-1278.
[26] Z?諭bczyk M，Undas A. Plasma fibrin clot structure and thromboembolism：clinical implications [J]. Pol Arch Intern Med，2017，127（12）：873-881.
[27] Humphries KH，Lee MK，Izadnegahdar M，et al. Sex Differences in Diagnoses，Treatment，and Outcomes for Emergency Department Patients With Chest Pain and Elevated Cardiac Troponin [J]. Acad Emerg Med，2018，25（4）：413-424.
[28] Kaltsas E，Chalikias G，Tziakas D. The Incidence and the Prognostic Impact of Acute Kidney Injury in Acute Myocardial Infarction Patients：Current Preventive Strategies [J]. Cardiovasc Drugs Ther，2018，32（1）：81-98.
[29] Hwang D，Kim HK，Lee JM，et al. Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients [J]. Circ J，2018，82（4）：1112-1120.
[30] Mitchell D，Guertin JR，Dubois A，et al. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention [J]. Mol Diagn Ther，2018，22（2）：241-254.
2018, Vol. 15 
京公网安备 11010502046598号